Application of vitamin D-binding protein as a marker in the diagnosis of depression in psychiatric diseases

Abstract

The invention discloses the application of vitamin D binding protein as a marker in the diagnosis of mental disease depression, and specifically refers to the application of a reagent for detecting the content of vitamin D binding protein in the preparation of reagents for diagnosing mental disease depression. The present invention shows that vitamin D-binding protein is differentially expressed in the plasma of schizophrenia, bipolar mania, depression and non-mental disease control subjects, and only specifically increases in the plasma of patients with depression; by using the protein alone as Detection of peripheral blood biomarkers for the diagnosis of depression can significantly improve the accuracy of differential diagnosis between depression and healthy people or other mental diseases such as schizophrenia and bipolar mania. Therefore, the detection of vitamin D binding protein content has high clinical application value in the diagnosis of depression, and provides a new way for the rapid and effective diagnosis of depression in mental diseases.

Description

technical field [0001] The invention belongs to the field of biological sciences, relates to rapid, convenient and specific differential diagnosis of mental diseases such as depression, and in particular relates to the application of vitamin D binding protein as a marker in the diagnosis of mental diseases and depression. Background technique [0002] Depression, also known as depression, is a class of emotional disorders characterized by depressed mood. According to the WHO report, depression will become the second leading disease in the world in 2020 and the leading cause of death and disability in 2030. The current clinical diagnosis of depression and other mental diseases mainly refers to "Chinese Classification and Diagnostic Criteria of Mental Disorders (Third Edition)" (CCMD-3), the United States' "International Classification of Diseases Tenth Edition" (ICD-10), " Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and Diagnostic and Stati...

AI Technical Summary

Problems solved by technology

The current clinical diagnosis of depression and other mental diseases mainly refers to "Chinese Classification and Diagnostic Criteria of Mental Disorders (Third Edition)" (CCMD-3), the United States' "International Classification of Diseases Tenth Edition" (ICD-10), " Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), but the method itself suffers from a serious drawback: subjectivity Strong, poor diagnostic consistency and high misdiagnosis rate

Since the detection of VDB in the brain is almost difficult to achieve in vivo, and peripheral plasma is relatively easy to obtain, there is no use of VDB as a differential diagnosis between depression and other mental diseases (such as schizophrenia, bipolar mania, etc.) Biomarker Research

Images